Fund moves
34.7%Stake
A Schedule 13D means the holder owns more than 5% and keeps the option to push for changes: board seats, a sale, buybacks. It must be filed within 5 business days.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
DAVI · NASDAQ · Surgical & Medical Instruments & Apparatus · Foreign private issuer
Davion Healthcare (DAVI) · oqro.io/stocks/DAVI · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$1.00−0.07 (−6.54%)
Close of Nov 19, 2026, vs Nov 18 · end-of-day
Yes. Insiders of Davion Healthcare (DAVI) filed 2 open-market purchases in the last 90 days; the latest was filed on Nov 18, 2026.
Since 2026, Davion Healthcare insiders reported 2 open-market purchases and 0 sales on Forms 4 and 5, with purchases in 1 different year, most recently 2026.
No open-market sale by an insider of Davion Healthcare (DAVI) was filed with the SEC in the last 90 days.
No trade in Davion Healthcare (DAVI) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−91.4% (−$10.65) from Oct 22, 2026 to Nov 19, 2026 · adjusted daily closes
Adjusted close went from $11.65 on Oct 22, 2026 to $1.00 on Nov 19, 2026 (−91.4%). Disclosed in this range: 2 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Surgical & Medical Instruments & Apparatus company based in Clonakilty, Ireland. Foreign private issuer: reports on Form 20-F or 40-F.
Surgical & Medical Instruments & Apparatus company based in Clonakilty, Ireland. Foreign private issuer: reports on Form 20-F or 40-F. Its directors and officers file insider-trading forms (Form 4) only since 18 March 2026.
Last 12 months
Not enough history
Market value
–
Short interest: 618K shares sold short, +100.0% vs the previous count, 1.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Fund moves
A Schedule 13D means the holder owns more than 5% and keeps the option to push for changes: board seats, a sale, buybacks. It must be filed within 5 business days.
Insider buying
Traded Nov 17 · filed 1 day later
Since the trade −2.9% · S&P 500 −2.3% · to Nov 19
A Davion Healthcare director paid $9.8K out of pocket for Davion Healthcare shares. 1 other person at Davion Healthcare bought some too, in the same month. It was the first purchase in over a year.
Insider buying
Traded Nov 16 · filed 1 day later
Since the trade −2.0% · S&P 500 −3.3% · to Nov 19
A Davion Healthcare director paid $26K out of pocket for Davion Healthcare shares. 1 other person at Davion Healthcare bought some too, in the same month. It was the first purchase in over a year.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Company reports, price and press
Things to keep in mind
Insiders of Davion Healthcare reported 2 open-market purchases and 0 sales since 2026; purchases in 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $36K2×2 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Every annual report has a section where the company's managers explain the year's results (Item 5, Operating and financial review). In this report it runs to about 5,000 words.
Davion Healthcare Plc is a pre-revenue company focused exclusively on the development and commercialization of non-invasive home tests for the early detection of health anomalies. Our home tests are non-diagnostic, focusing on early detection of potential health anomalies, for which if identified, further clinical tests outside of the scope of our products would be required. We have focused our unique technologies on an exceptionally affordable home-based test system. Our strength as a Company at this early stage is twofold, that we possess our own intellectual property, patents and technology; and that to date, there are no other known competitors attempting to utilize like-technologies.
And 11 more headings in the filing.
Source: SEC EDGAR, Form 20-F filed Apr 30, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Fails to deliver: 424K shares (about $1.39M) were not delivered on time for settlement on Oct 29, 2026. SEC fails-to-deliver data.
Fails to deliver have many causes, including processing delays, and are often resolved within days.
Off-exchange trading: FINRA has published no off-exchange figures for DAVI in the last six months.
Latest annual report filed Apr 30, 2026. Read the filing
46 risk factor headings in this report. There is no earlier annual report to compare it with.
Source: SEC EDGAR, Form 20-F filed Apr 30, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.